Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
NCT05983237
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
Fluzoparib Camrelizumab Temozolomide
Sponsor
Jun Guo